Search
Dynavax Technologies Corp
DVAXAdd to Watchlist
15.500USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.76BMarket Cap
LossP/E TTM
More Details of Dynavax Technologies Corp Company
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Dynavax Technologies Corp Info
Ticker SymbolDVAX
Company nameDynavax Technologies Corp
IPO dateFeb 19, 2004
CEOSpencer (Ryan)
Number of employees405
Security typeOrdinary Share
Fiscal year-endFeb 19
Address2100 Powell Street
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15108485100
Websitehttps://www.dynavax.com/
Ticker SymbolDVAX
IPO dateFeb 19, 2004
CEOSpencer (Ryan)
Company Executives of Dynavax Technologies Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+50.50%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+54.83%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
46.64K
-135.79%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+23.19%
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
16.47K
-2305.20%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
1.44K
--
Dr. Francis R. Cano, Ph.D.
Dr. Francis R. Cano, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+50.50%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+54.83%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
46.64K
-135.79%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+23.19%
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
16.47K
-2305.20%
FAQs
Who are the top five shareholders of Dynavax Technologies Corp?
The top five shareholders of Dynavax Technologies Corp are: Dr. Robert (Rob) Janssen, M.D.
How many institutions hold shares of Dynavax Technologies Corp (DVAX)?
As of 2026Q1, 569 institutions hold shares of Dynavax Technologies Corp, with a combined market value of approximately 82.18M, accounting for 72.29% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -46773394.00.
What is the biggest source of revenue for Dynavax Technologies Corp?
In 2026Q1, the HEPLISAV-B business generated the highest revenue for Dynavax Technologies Corp, amounting to 89.95M and accounting for 94.81% of total revenue.